APGE vs. LNTH, LEGN, TGTX, BBIO, AXSM, TLX, BPMC, GRFS, NUVL, and KRYS
Should you be buying Apogee Therapeutics stock or one of its competitors? The main competitors of Apogee Therapeutics include Lantheus (LNTH), Legend Biotech (LEGN), TG Therapeutics (TGTX), BridgeBio Pharma (BBIO), Axsome Therapeutics (AXSM), Telix Pharmaceuticals Limited American Depositary Shares (TLX), Blueprint Medicines (BPMC), Grifols (GRFS), Nuvalent (NUVL), and Krystal Biotech (KRYS). These companies are all part of the "pharmaceutical products" industry.
Apogee Therapeutics vs.
Apogee Therapeutics (NASDAQ:APGE) and Lantheus (NASDAQ:LNTH) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, media sentiment, profitability, community ranking, dividends, valuation, institutional ownership and earnings.
Lantheus has a net margin of 28.57% compared to Apogee Therapeutics' net margin of 0.00%. Lantheus' return on equity of 44.29% beat Apogee Therapeutics' return on equity.
79.0% of Apogee Therapeutics shares are held by institutional investors. Comparatively, 99.1% of Lantheus shares are held by institutional investors. 36.1% of Apogee Therapeutics shares are held by insiders. Comparatively, 1.5% of Lantheus shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Apogee Therapeutics has a beta of 2.46, meaning that its share price is 146% more volatile than the S&P 500. Comparatively, Lantheus has a beta of 0.38, meaning that its share price is 62% less volatile than the S&P 500.
Apogee Therapeutics presently has a consensus target price of $92.17, indicating a potential upside of 131.05%. Lantheus has a consensus target price of $129.43, indicating a potential upside of 29.73%. Given Apogee Therapeutics' higher probable upside, equities analysts plainly believe Apogee Therapeutics is more favorable than Lantheus.
Lantheus has higher revenue and earnings than Apogee Therapeutics. Apogee Therapeutics is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.
In the previous week, Lantheus had 21 more articles in the media than Apogee Therapeutics. MarketBeat recorded 26 mentions for Lantheus and 5 mentions for Apogee Therapeutics. Apogee Therapeutics' average media sentiment score of 1.38 beat Lantheus' score of 0.70 indicating that Apogee Therapeutics is being referred to more favorably in the media.
Lantheus received 314 more outperform votes than Apogee Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Apogee Therapeutics an outperform vote while only 66.02% of users gave Lantheus an outperform vote.
Summary
Lantheus beats Apogee Therapeutics on 11 of the 16 factors compared between the two stocks.
Get Apogee Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for APGE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Apogee Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:APGE) was last updated on 3/25/2025 by MarketBeat.com Staff
Buy APGE Stock Free APGE Stock Alerts